Health Care [ 11/12 ] | Life Sciences Tools & Services [ 43/75 ]
NYSE | Common Stock
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products.
Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research.
It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD.
Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 24, 24 | 5.37 Increased by +4.27% | 5.12 Increased by +4.88% |
| Apr 24, 24 | 5.11 Increased by +1.59% | 4.71 Increased by +8.49% |
| Jan 31, 24 | 5.67 Increased by +5.00% | 5.64 Increased by +0.53% |
| Oct 25, 23 | 5.69 Increased by +12.01% | 5.61 Increased by +1.43% |
| Jul 26, 23 | 5.15 Decreased by -6.53% | 5.43 Decreased by -5.16% |
| Apr 26, 23 | 5.03 Decreased by -30.62% | 5.03 |
| Feb 1, 23 | 5.40 Decreased by -17.43% | 5.20 Increased by +3.85% |
| Oct 26, 22 | 5.08 Decreased by -11.81% | 4.81 Increased by +5.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 10.35 B Decreased by -3.41% | 1.33 B Increased by +3.03% | Increased by +12.84% Increased by +6.66% |
| Dec 31, 23 | 10.89 B Decreased by -4.93% | 1.63 B Increased by +3.43% | Increased by +14.97% Increased by +8.78% |
| Sep 30, 23 | 10.57 B Decreased by -0.96% | 1.72 B Increased by +14.72% | Increased by +16.22% Increased by +15.83% |
| Jun 30, 23 | 10.69 B Decreased by -2.58% | 1.36 B Decreased by -18.21% | Increased by +12.74% Decreased by -16.04% |
| Mar 31, 23 | 10.71 B Decreased by -9.38% | 1.29 B Decreased by -41.81% | Increased by +12.04% Decreased by -35.79% |
| Dec 31, 22 | 11.45 B Increased by +6.99% | 1.58 B Decreased by -4.95% | Increased by +13.76% Decreased by -11.16% |
| Sep 30, 22 | 10.68 B Increased by +14.44% | 1.50 B Decreased by -21.40% | Increased by +14.00% Decreased by -31.31% |
| Jun 30, 22 | 10.97 B Increased by +18.30% | 1.66 B Decreased by -8.97% | Increased by +15.17% Decreased by -23.05% |